INT29086

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 1987
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 37
Total Number 37
Disease Relevance 7.49
Pain Relevance 14.98

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
brain 4
arcuate nucleus 1
nerve cells 1
Sertoli cell 1
Sert1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Serotonin 127 100.00 Very High Very High Very High
cocaine 43 99.96 Very High Very High Very High
antagonist 29 99.90 Very High Very High Very High
fluoxetine 119 99.78 Very High Very High Very High
sSRI 55 99.54 Very High Very High Very High
antidepressant 13 99.50 Very High Very High Very High
Opioid 2 99.50 Very High Very High Very High
Morphine 14 99.28 Very High Very High Very High
Raphe 41 99.00 Very High Very High Very High
withdrawal 14 98.92 Very High Very High Very High
Disease Link Frequency Relevance Heat
Gliosis 25 99.90 Very High Very High Very High
Pulmonary Hypertension 28 99.84 Very High Very High Very High
Targeted Disruption 30 99.08 Very High Very High Very High
Increased Venous Pressure Under Development 15 98.92 Very High Very High Very High
Opiate Addiction 10 98.92 Very High Very High Very High
Cognitive Disorder 39 98.56 Very High Very High Very High
Attention Deficit Hyperactivity Disorder 165 98.18 Very High Very High Very High
Rheumatoid Arthritis 2 97.60 Very High Very High Very High
Death 25 96.54 Very High Very High Very High
Hypoxia 10 96.04 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Previous investigations had shown that inhibitor of serotonin reuptake transporter (SERT) could attenuate morphine withdrawal syndrome in adult animals.
Negative_regulation (inhibitor) of SERT associated with withdrawal, serotonin and morphine
1) Confidence 0.58 Published 2005 Journal Eur. J. Pharmacol. Section Abstract Doc Link 15814088 Disease Relevance 0.32 Pain Relevance 0.96
This result suggests that inhibitor of SERT may be of potential in treating neonatal morphine withdrawal syndrome.
Negative_regulation (inhibitor) of SERT associated with withdrawal and morphine
2) Confidence 0.58 Published 2005 Journal Eur. J. Pharmacol. Section Abstract Doc Link 15814088 Disease Relevance 0.49 Pain Relevance 1.30
Substitution of the indole N-1 position with methyl or ethyl groups gave a 10- to 30-fold decrease in affinity for hSERT, suggesting either a hydrogen-bonding interaction or limited steric tolerance in the region of the indole nitrogen.
Negative_regulation (decrease) of hSERT associated with tolerance
3) Confidence 0.57 Published 2005 Journal J. Med. Chem. Section Abstract Doc Link 16162005 Disease Relevance 0.07 Pain Relevance 0.26
The action of SSRIs is likely mediated by suppression of SERT activity.
Negative_regulation (suppression) of SERT associated with ssri
4) Confidence 0.55 Published 2008 Journal Life Sci. Section Abstract Doc Link 18482738 Disease Relevance 0.06 Pain Relevance 0.38
There is synergy between the inhibitory effects of 5-HT(1B) receptor antagonists and SERT inhibitors on 5-HT-induced pulmonary vasoconstriction.
Negative_regulation (inhibitors) of SERT associated with antagonist and increased venous pressure under development
5) Confidence 0.50 Published 2005 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 15659538 Disease Relevance 0.42 Pain Relevance 0.31
Inhibitors of SERT have been reported to attenuate or reverse experimental PAH, which makes them potential therapeutic options for the treatment of PAH in humans.
Negative_regulation (Inhibitors) of SERT associated with pulmonary hypertension
6) Confidence 0.49 Published 2009 Journal Clin. Exp. Pharmacol. Physiol. Section Abstract Doc Link 19473340 Disease Relevance 0.82 Pain Relevance 0.19
However, little is known about pathophysiological features after reversal or attenuation of PAH; moreover, the long-term therapeutic effects of SERT inhibitors on PAH remain undetermined.
Negative_regulation (inhibitors) of SERT associated with pulmonary hypertension
7) Confidence 0.49 Published 2009 Journal Clin. Exp. Pharmacol. Physiol. Section Abstract Doc Link 19473340 Disease Relevance 0.88 Pain Relevance 0.33
Serotonin uptake and radioligand binding assays revealed that rat and human SERTs show different sensitivities to some but not all transporter ligands; most tricyclic antidepressants were significantly more potent at the human SERT, relative to rat SERT, whereas d-amphetamine was a more potent inhibitor of rat SERT.
Negative_regulation (inhibitor) of SERT associated with tricyclic antidepressant and serotonin
8) Confidence 0.46 Published 1994 Journal Mol. Pharmacol. Section Abstract Doc Link 7969065 Disease Relevance 0 Pain Relevance 0.45
N,N-Dimethyl-2-(2-amino-4-methylthiophenylthio)benzylamine (SMe-ADAM, 1) is a highly potent and selective inhibitor of the serotonin transporter (SERT).
Negative_regulation (inhibitor) of SERT associated with serotonin
9) Confidence 0.44 Published 2006 Journal Nucl. Med. Biol. Section Abstract Doc Link 16459259 Disease Relevance 0 Pain Relevance 0.27
SERT antagonists (e.g., fluoxetine, cocaine) reduced total SERT expression levels and the time course of SERT expression.
Negative_regulation (reduced) of SERT associated with antagonist, cocaine and fluoxetine
10) Confidence 0.43 Published 2002 Journal J. Neurosci. Section Abstract Doc Link 11756522 Disease Relevance 0 Pain Relevance 0.31
We have revealed novel QTLs that modify the behavioral phenotypes of SERT deficiency in rats.
Negative_regulation (deficiency) of SERT
11) Confidence 0.41 Published 2010 Journal BMC Genet Section Body Doc Link PMC2874760 Disease Relevance 0.05 Pain Relevance 0
It was observed that the density of cortical SERT was significantly decreased with CMI (68%, P < 0.0001), FLX (67%, P < 0.0001), CIT (54%, P < 0.0001), and AMI (52%, P < 0.0001) treatment, when compared to the density of 120.7 +/- 4.0 fmol/mg protein in control rats, without altering the affinity (Kd) of [(3)H]paroxetine to the transporters.
Negative_regulation (decreased) of SERT associated with endep and fluoxetine
12) Confidence 0.38 Published 2008 Journal Neurochem. Res. Section Abstract Doc Link 18437564 Disease Relevance 0.15 Pain Relevance 1.18
The results suggest that chronic antidepressant treatment significantly down-regulates both cortical and hippocampal SERT in rat brain and SSRIs have high affinity for SERT than TCAs.
Negative_regulation (down-regulates) of SERT in brain associated with antidepressant, tricyclic antidepressant and ssri
13) Confidence 0.38 Published 2008 Journal Neurochem. Res. Section Abstract Doc Link 18437564 Disease Relevance 0 Pain Relevance 1.04
Blockade of SERT with fluoxetine (1 microM) increased the peak compression-evoked release to 19 +/- 9 microM, and the background levels of 5-HT increased to 11 +/- 7 microM (P < 0.05, n = 7).
Negative_regulation (Blockade) of SERT associated with fluoxetine
14) Confidence 0.37 Published 2008 Journal Am. J. Physiol. Gastrointest. Liver Physiol. Section Abstract Doc Link 18927211 Disease Relevance 0 Pain Relevance 0.45
This study aimed to demonstrate real-time SERT activity in ileal mucosa and to assess the effects of SERT inhibition using fluoxetine.
Negative_regulation (inhibition) of SERT associated with fluoxetine
15) Confidence 0.37 Published 2008 Journal Am. J. Physiol. Gastrointest. Liver Physiol. Section Abstract Doc Link 18927211 Disease Relevance 0 Pain Relevance 0.35
Moreover, studies performed in VC from mutant rats lacking SERT showed no differences in 5-HT uptake compared with VC from wild type.
Negative_regulation (lacking) of SERT
16) Confidence 0.37 Published 2008 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 18322152 Disease Relevance 0.17 Pain Relevance 0.20
Furthermore, we compared the functional effects of SERT inhibitors and 5-HT receptor antagonists against 5-HT-induced vasoconstriction of pulmonary arteries.
Negative_regulation (inhibitors) of SERT associated with antagonist and increased venous pressure under development
17) Confidence 0.37 Published 2005 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 15659538 Disease Relevance 0.47 Pain Relevance 0.24
Using LLC-PK(1) cells specifically expressing the individual transporter (i.e. dopamine [DAT], norepinephrine [NET], and SERT, respectively), ODAM showed a strong inhibition on SERT (K(i) = 0.12 +/- 0.02 nM).
Negative_regulation (inhibition) of SERT associated with dopamine
18) Confidence 0.36 Published 2000 Journal Nucl. Med. Biol. Section Abstract Doc Link 10773546 Disease Relevance 0.07 Pain Relevance 0.47
The constitutive absence of the SERT in mice causes changes in the functioning of 5-HT receptors (Fabre et al. 2000; Bouali et al. 2003), so that changes in behaviour may be the result of adaptations that have occurred during development.
Negative_regulation (absence) of SERT
19) Confidence 0.36 Published 2007 Journal Psychopharmacology (Berl) Section Body Doc Link PMC2048539 Disease Relevance 0.36 Pain Relevance 0.07
Because social behaviour is reduced in peri-adolescent and adult SERT?
Negative_regulation (reduced) of SERT
20) Confidence 0.36 Published 2007 Journal Psychopharmacology (Berl) Section Body Doc Link PMC2048539 Disease Relevance 0.38 Pain Relevance 0.28

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox